BioAge Labs Business Summary

BioAge Labs, Inc. (BIOA) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic research collaborations and licensing agreements, most notably a multi-year partnership with Novartis which contributed $9.0 million in collaboration revenue for FY2025. The company operates through a data-driven business model centered on its proprietary "human-first" discovery platform, which leverages multi-omics analysis of longitudinal biobank data to identify novel targets in metabolic aging. Its primary business segments are focused on its clinical pipeline: lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor targeting cardiovascular risk and diabetic macular edema, and its APJ agonist program for obesity. BioAge competes directly with metabolic heavyweights Eli Lilly and Novo Nordisk, as well as clinical-stage firms like Ventyx Biosciences and Viking Therapeutics. The company distinguishes itself by developing oral, small-molecule "exercise mimetics" and anti-inflammatory therapies that target the underlying biology of aging rather than traditional incretin-based pathways. BioAge was co-founded by CEO Kristen Fortney, PhD, a specialist in the bioinformatics of aging, and COO Eric Morgen, MD, who brings a background in medical informatics and pathology. The executive leadership team includes CFO Dov Goldstein, MD, MBA, formerly of Lexeo Therapeutics, and CMO Paul Rubin, MD, who has overseen over 30 successful INDs. The company’s strategic direction is further guided by Board Chair Jean-Pierre Garnier, PhD, the former CEO of GlaxoSmithKline. BioAge is backed by a high-pedigree investor base including Andreessen Horowitz (a16z), Khosla Ventures, Felicis Ventures, and Sofinnova Investments. As of March 2026, the company maintains a robust balance sheet with approximately $285 million in cash, bolstered by a recent $132.3 million follow-on offering, providing a projected operational runway through 2029.